Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-62296
Soyka, Jan D; Muster, Marco A; Schmid, Daniel T; Seifert, Burkhardt; Schick, Ulrike; Miralbell, Raymond; Jorcano, Sandra; Zaugg, Kathrin; Seifert, Hans-Helge; Veit-Haibach, Patrick; Strobel, Klaus; Schaefer, Niklaus G; Husarik, Daniela B; Hany, Thomas F (2012). Clinical impact of (18)F-choline PET/CT in patients with recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 39(6):936-943.
PDF - Registered users only
View at publisher
PURPOSE: To investigate the clinical value of (18)F-fluorocholine PET/CT (CH-PET/CT) in treatment decisions in patients with recurrent prostate cancer (rPCA).
METHODS: The study was a retrospective evaluation of 156 patients with rPCA and CH-PET/CT for restaging. Questionnaires for each examination were sent to the referring physicians 14-64 months after examination. Questions included information regarding initial extent of disease, curative first-line treatment, and the treatment plan before and after CH-PET/CT. Additionally, PSA values at diagnosis, after initial treatment, before CH-PET/CT and at the end of follow-up were also obtained from the questionnaires.
RESULTS: Mean follow-up was 42 months. The mean Gleason score was 6.9 at initial diagnosis. Initial treatment was: radical prostatectomy in 110 patients, radiotherapy in 39, and combined prostatectomy and radiotherapy in 7. Median PSA values before CH-PET/CT and at the end of follow-up were 3.40 ng/ml and 0.91 ng/ml. PSA levels remained stable, decreased or were below measurable levels in 108 patients. PSA levels increased in 48 patients. In 75 of the 156 patients (48%) the treatment plan was changed due to the CH-PET/CT findings. In 33 patients the therapeutic plan was changed from palliative treatment to treatment with curative intent. In 15 patients treatment was changed from curative to palliative. In 8 patients treatment was changed from curative to another strategy and in 2 patients from one palliative strategy to another. In 17 patients the treatment plan was adapted.
CONCLUSION: CH-PET/CT has an important impact on the therapeutic strategy in patients with rPCA and can help to determine an appropriate treatment.
243 downloads since deposited on 21 May 2012
62 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Radiation Oncology
04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||21 May 2012 11:51|
|Last Modified:||05 Apr 2016 15:48|
|Additional Information:||The final publication is available at www.springerlink.com|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page